Brenntag (BNR) Q2 2025 earnings summary

Executive summary

• Q2 2025 sales were EUR 3.9 billion, down 4% year-over-year, with operating EBITA at EUR 246 million, a 14% decline, and EPS at EUR 0.30, impacted by special items and impairments.

• High economic and geopolitical uncertainty, unresolved global tariff discussions, and FX volatility dampened demand and sentiment, especially in the Essentials division.

• Cost containment delivered EUR 30 million in Q2 savings, with a focus on price/margin management and sustainability initiatives.

• Two acquisitions closed in Q2 2025 to expand biopharma and hazardous substance storage capabilities.

• CEO Christian Kohlpaintner announced his last earnings call, with Jens Birgersson to succeed him in September 2025.

Financial highlights

• Operating gross profit was EUR 974 million in Q2, down 2% year-over-year, with gross margin slightly up to 25.2%.

• Operating EBITDA for Q2 was EUR 246 million, down 14% year-over-year; for H1, it was EUR 689.3 million, down 5.3%.

• Free cash flow for Q2 was EUR 153 million, slightly below last year; for H1, it was EUR 316.2 million, down 5%.

• Earnings per share dropped to EUR 0.30 in Q2 and EUR 1.23 for H1, mainly due to special items and impairments.

• Net income for Q2 was EUR 43.2 million, and for H1, profit after tax was EUR 178.9 million.

Outlook and guidance

• Full-year 2025 operating EBITA guidance was revised to EUR 950–1,050 million, reflecting FX headwinds and persistent market uncertainty.

• Guidance assumes an average EUR/USD FX rate of 1.13 for 2025, with a second-half run rate of 1.16.

• Management expects continued weak demand and pricing pressure in H2 2025, with global industrial production forecast to stagnate.

• Tax rate for 2025 expected at 35–37% due to one-time effects; underlying rate 28–30%.

• July showed better performance than June, but September is seen as decisive for Q3.